Literature DB >> 22310028

Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region.

D Prokofyeva, N Bogdanova, M Bermisheva, G Zinnatullina, P Hillemanns, E Khusnutdinova, T Dörk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22310028     DOI： 10.1111/j.1399-0004.2011.01824.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN： 0009-9163            Impact factor:   4.438


× No keyword cloud information.
  9 in total

1.  Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.

Authors:  Natalia Bogdanova; Alexandr V Togo; Magdalena Ratajska; Wojtek Kluźniak; Zalina Takhirova; Theresa Tarp; Darya Prokofyeva; Marina Bermisheva; Grigoriy A Yanus; Tatiana V Gorodnova; Anna P Sokolenko; Alina Kuźniacka; Amira Podolak; Maciej Stukan; Dominika Wokołorczyk; Jacek Gronwald; Danuta Vasilevska; Vilius Rudaitis; Ingo B Runnebaum; Matthias Dürst; Tjoung-Won Park-Simon; Peter Hillemanns; Natalia Antonenkova; Elza Khusnutdinova; Janusz Limon; Jan Lubinski; Cezary Cybulski; Evgeny Imyanitov; Thilo Dörk
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

2.  Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.

Authors:  Ciyu Yang; Angela G Arnold; Magan Trottier; Yukio Sonoda; Nadeem R Abu-Rustum; Oliver Zivanovic; Mark E Robson; Zsofia K Stadler; Michael F Walsh; David M Hyman; Kenneth Offit; Liying Zhang
Journal:  Breast Cancer Res Treat       Date:  2016-10-18       Impact factor: 4.872

3.  Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.

Authors:  Zhi L Teo; Daniel J Park; Elena Provenzano; Catherine A Chatfield; Fabrice A Odefrey; Tu Nguyen-Dumont; James G Dowty; John L Hopper; Ingrid Winship; David E Goldgar; Melissa C Southey
Journal:  Breast Cancer Res       Date:  2013-02-28       Impact factor: 6.466

4.  Molecular genetics of breast and ovarian cancer: recent advances and clinical implications.

Authors:  N Bogdanova; T Dörk
Journal:  Balkan J Med Genet       Date:  2012-12       Impact factor: 0.519

5.  Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management.

Authors:  Thomas Paul Slavin; Mariana Niell-Swiller; Ilana Solomon; Bita Nehoray; Christina Rybak; Kathleen R Blazer; Jeffrey N Weitzel
Journal:  Front Oncol       Date:  2015-09-29       Impact factor: 6.244

6.  Hereditary breast cancer: ever more pieces to the polygenic puzzle.

Authors:  Natalia Bogdanova; Sonja Helbig; Thilo Dörk
Journal:  Hered Cancer Clin Pract       Date:  2013-09-11       Impact factor: 2.857

7.  No evidence for PALB2 methylation in high-grade serous ovarian cancer.

Authors:  Thomas Mikeska; Kathryn Alsop; Gillian Mitchell; David Dl Bowtell; Alexander Dobrovic
Journal:  J Ovarian Res       Date:  2013-04-12       Impact factor: 4.234

8.  Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.

Authors:  Marc Tischkowitz; Nelly Sabbaghian; Nancy Hamel; Carly Pouchet; William D Foulkes; Anne-Marie Mes-Masson; Diane M Provencher; Patricia N Tonin
Journal:  BMC Med Genet       Date:  2013-01-09       Impact factor: 2.103

9.  Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore.

Authors:  Sze Yee Phuah; Sheau Yee Lee; Peter Kang; In Nee Kang; Sook-Yee Yoon; Meow Keong Thong; Mikael Hartman; Jen-Hwei Sng; Cheng Har Yip; Nur Aishah Mohd Taib; Soo-Hwang Teo
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.